{"id":977376,"date":"2026-06-30T16:28:04","date_gmt":"2026-06-30T20:28:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"modified":"2026-06-30T16:28:04","modified_gmt":"2026-06-30T20:28:04","slug":"sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","title":{"rendered":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>\nThe employees received in the aggregate 151,305 restricted stock units (\u201cRSUs\u201d). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee\u2019s continued employment with Sarepta on such vesting date. Employees did not receive options to purchase shares of Sarepta\u2019s common stock.<\/p>\n<p><strong><i>About Sarepta Therapeutics<br \/>\n<br \/><\/i><\/strong>Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sarepta.com&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=www.sarepta.com&amp;index=1&amp;md5=7fd89b3c18061150f786522148ad52c2\"><b>www.sarepta.com<\/b><\/a> or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsarepta-therapeutics&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=61f22dcb15656e787c1d452fbfa22cde\"><b>LinkedIn<\/b><\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FSarepta&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=X&amp;index=3&amp;md5=284552a409d708468542420c89708e06\"><b>X<\/b><\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.instagram.com%2Fsareptatherapeutics%2F&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=Instagram&amp;index=4&amp;md5=5057bf6a29cadcccb6c2cd3a32068bab\"><b>Instagram<\/b><\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FSarepta-Therapeutics-208950446535427%2F&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=012545ee22ffeab2c9fcfd61bba86c4d\"><b>Facebook<\/b><\/a>.<\/p>\n<p><strong><i>Internet Posting of Information<br \/>\n<br \/><\/i><\/strong><i>We routinely post information that may be important to investors in the &#8216;For Investors&#8217; section of our website at <\/i><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sarepta.com%2F&amp;esheet=54563064&amp;newsitemid=20260630221318&amp;lan=en-US&amp;anchor=www.sarepta.com&amp;index=6&amp;md5=84e623497b849d90607427909ab6b726\"><i>www.sarepta.com<\/i><\/a><i>. We encourage investors and potential investors to consult our website regularly for important information about us.<\/i><\/p>\n<p>\nSource: Sarepta Therapeutics, Inc.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260630221318\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260630221318\/en\/<\/a><\/span><\/p>\n<p><b><i>Investor Contact:<br \/>\n<\/i><\/b><br \/>Ian Estepan, 617-274-4052 <a rel=\"nofollow\" href=\"mailto:iestepan@sarepta.com\">iestepan@sarepta.com<br \/>\n<\/a><br \/>Ryan Wong, 617-800-4112, <a rel=\"nofollow\" href=\"mailto:rwong@sarepta.com\">rwong@sarepta.com<br \/>\n<\/a><br \/>Tam Thornton, 617-803-3825, <a rel=\"nofollow\" href=\"mailto:tthornton@sarepta.com\">tthornton@sarepta.com<br \/>\n<\/a><\/p>\n<p><b><i>Media Contact:<br \/>\n<\/i><\/b><br \/>Tracy Sorrentino, 617-301-8566, <a rel=\"nofollow\" href=\"mailto:tsorrentino@sarepta.com\">tsorrentino@sarepta.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health FDA Genetics Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260630221318\/en\/1815332\/3\/Sarepta_Corporate-_Stacked_Logo_%28Full_Color%29.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received in the aggregate 151,305 restricted stock units (\u201cRSUs\u201d). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-977376","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received in the aggregate 151,305 restricted stock units (\u201cRSUs\u201d). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested &hellip; Continue reading &quot;Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-30T20:28:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2026-06-30T20:28:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"},\"wordCount\":341,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\",\"name\":\"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-06-30T20:28:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_locale":"en_US","og_type":"article","og_title":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211; Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta\u2019s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 30 individuals hired by Sarepta in the second quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received in the aggregate 151,305 restricted stock units (\u201cRSUs\u201d). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested &hellip; Continue reading \"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-30T20:28:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2026-06-30T20:28:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"},"wordCount":341,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/","name":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-06-30T20:28:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260630221318r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/977376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=977376"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/977376\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=977376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=977376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=977376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}